🔥 Premium AI-powered Stock Picks from InvestingPro Now up to 50% OffCLAIM SALE

Moderna price target raised at Oppenheimer after RSV vaccine approval

Published 06/12/2024, 07:48 PM
© Reuters.
PFE
-
MRNA
-

Oppenheimer upped their price target on Moderna (NASDAQ:MRNA) after the US drugmaker recently saw its respiratory syncytial virus (RSV) vaccine, known as mRESVIA, approved by the Food and Drug Administration (FDA).

According to Oppenheimer, mResvia is entering the adult market (ages 60 and above), where it will compete with two established vaccines from GSK and Pfizer (NYSE:PFE).

RSV poses a significant economic burden on societies, nearly as large as influenza. In the US, while most RSV infections are mild, severe cases can result in hospitalization and, occasionally, death.

In 2023, GSK and Pfizer both received approval for their highly competitive RSV vaccines. Now, mResvia has become the third RSV vaccine approved for adults 60 and older.

“We increase US penetration estimates as we believe mResvia is competitive as an RSV vaccine, although expectations might be too low,” analysts said in a note.

“With a projected total accessible market (TAM) of ~$10B currently, growing to $12.5B by 2027, we believe that a $1B–$2B revenue run rate is viable for mResvia,” they added. “However, with MRNA's Phase 3 data from higher-risk and frail adults, combined with a strong product profile, upside is possible.”

As such, the firm raised its target 12 to 18-month target on MRNA from $163 to $179, implying more than 20% upside from the last closing price.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.